22:04

CALQUENCE® (acalabrutinib) ELEVATE-TN, Including 6-Year Median Follow-Up Data – Dr O’ Brien, MD

18:35

CALQUENCE® (acalabrutinib) ACE-CL-001 (ibrutinib-intolerant cohort) – Dr Raval, MD

19:00

CALQUENCE® (acalabrutinib) ELEVATE-RR and ASCEND Data – Dr Ma, MD

15:59

CALQUENCE® (acalabrutinib) Long-Term Data – Dr Brem, MD

17:23

CALQUENCE® (acalabrutinib) Pooled Safety Analysis – Dr Pinilla-lbarz, MD

20:01

CALQUENCE® (acalabrutinib) MAIC of ASCEND and ALPINE – Dr Skarbnik, MD

12:20

CALQUENCE® (acalabrutinib) Perspectives: Dr Alexey Danilov, MD, PhD

15:22

CALQUENCE® (acalabrutinib) ELEVATE-TN data, incl. High-Risk Subgroups – Dr Abutalib, MD